Top

Published in:

28-02-2024 | Glaucoma | Review Article

Rho Kinase Inhibitors: Strategies in Glaucoma Treatment in Older Adults

Authors: Emily Schehlein, Alan Robin

Published in: Drugs & Aging | Issue 5/2024

Abstract

Glaucoma is a leading cause of irreversible blindness which preferentially affects older individuals. No medications or therapies which are currently in our arsenal actually treat glaucoma itself. We know that intraocular pressure (IOP) is currently the only modifiable risk factor for glaucoma. The primary treatments for glaucoma include medications, laser therapies, and surgical therapies. The Rho kinase inhibitors are the newest class of medications currently on the market and in development for topical IOP-lowering therapy. Studies have shown their ability to lower eye pressure individually and in combination with other medications. Their ability to potentially provide neuroprotective effects for disease modification also gives this class exciting potential for glaucoma treatment.

Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90(3):262–7. https://doi.org/10.1136/bjo.2005.081224.CrossRefPubMedPubMedCentral

Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. Lancet Glob Health. 2021;9(2):e144-e160. https://doi.org/10.1016/S2214-109X(20)30489-7

Tham Y-C, Li X, Wong TY, Quigley HA, Aung T, Cheng C-Y. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081–90. https://doi.org/10.1016/j.ophtha.2014.05.013.CrossRefPubMed

Friedman DS, Jampel HD, Muñoz B, West SK. The prevalence of open-angle glaucoma among blacks and whites 73 years and older: the Salisbury Eye Evaluation Glaucoma Study. Arch Ophthalmol. 2006;124(11):1625–30. https://doi.org/10.1001/archopht.124.11.1625.CrossRefPubMed

Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol (Chicago, Ill 1960). 2002;120(6):701–30.CrossRef

Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol (Chicago, Ill 1960). 2003;121(1):48–56.CrossRef

Gazzard G, Konstantakopoulou E, Garway-Heath D, et al. LiGHT trial: 6-year results of primary selective laser trabeculoplasty versus eye drops for the treatment of glaucoma and ocular hypertension. Ophthalmology. 2022. https://doi.org/10.1016/j.ophtha.2022.09.009.CrossRefPubMed

Pereira ICF, van de Wijdeven R, Wyss HM, Beckers HJM, den Toonder JMJ. Conventional glaucoma implants and the new MIGS devices: a comprehensive review of current options and future directions. Eye (Lond). 2021;35(12):3202–21. https://doi.org/10.1038/s41433-021-01595-x.CrossRefPubMed

Rathi S, Andrews CA, Greenfield DS, Stein JD. Trends in glaucoma surgeries performed by glaucoma subspecialists versus nonsubspecialists on medicare beneficiaries from 2008 through 2016. Ophthalmology. 2021;128(1):30–8. https://doi.org/10.1016/j.ophtha.2020.06.051.CrossRefPubMed

10.

AbbVie. Allergan Receives FDA Approval for DURYSTA^TM. https://news.abbvie.com/news/allergan-press-releases/allergan-receives-fda-approval-for-durysta-bimatoprost-implant-first-and-only-intracameral-biodegradable-sustained-release-implant-to-lower-intraocular-pressure-in-open-angle-glaucoma-or-ocular-hypertension-patients.htm. Published 2020. Accessed 17 Dec 2023

11.

Medeiros FA, Walters TR, Kolko M, et al. Phase 3, randomized, 20-month study of bimatoprost implant in open-angle glaucoma and ocular hypertension (ARTEMIS 1). Ophthalmology. 2020;127(12):1627–41. https://doi.org/10.1016/j.ophtha.2020.06.018.CrossRefPubMed

12.

Shirley M. Bimatoprost implant: first approval. Drugs Aging. 2020;37(6):457–62. https://doi.org/10.1007/s40266-020-00769-8.CrossRefPubMedPubMedCentral

13.

Trese MGJ, Lewis AW, Blachley TS, Stein JD, Moroi SE. Changing initial glaucoma medical therapy increases healthcare resource utilization. J Ocul Pharmacol Ther. 2017;33(8):591–7. https://doi.org/10.1089/jop.2017.0051.CrossRefPubMed

14.

Musch DC, Lichter PR, Guire KE, Standardi CL. The Collaborative Initial Glaucoma Treatment Study: study design, methods, and baseline characteristics of enrolled patients. Ophthalmology. 1999;106(4):653–62.CrossRefPubMed

15.

Hennessy AL, Katz J, Covert D, et al. A video study of drop instillation in both glaucoma and retina patients with visual impairment. Am J Ophthalmol. 2011;152(6):982–8. https://doi.org/10.1016/j.ajo.2011.05.015.CrossRefPubMed

16.

Newman-Casey PA, Robin AL, Blachley T, et al. The most common barriers to glaucoma medication adherence: a cross-sectional survey. Ophthalmology. 2015;122(7):1308–16. https://doi.org/10.1016/j.ophtha.2015.03.026.CrossRefPubMed

17.

Varma R, Lee PP, Goldberg I, Kotak S. An assessment of the health and economic burdens of glaucoma. Am J Ophthalmol. 2011;152(4):515–22. https://doi.org/10.1016/j.ajo.2011.06.004.CrossRefPubMedPubMedCentral

18.

Rein DB, Zhang P, Wirth KE, et al. The economic burden of major adult visual disorders in the United States. Arch Ophthalmol. 2006;124(12):1754–60. https://doi.org/10.1001/archopht.124.12.1754.CrossRefPubMed

19.

Schehlein EM, Im LT, Robin AL, Onukwugha E, Saeedi OJ. Nonmedical out-of-pocket patient and companion expenditures associated with glaucoma care. J Glaucoma. 2017;26(4):343–8. https://doi.org/10.1097/IJG.0000000000000619.CrossRefPubMedPubMedCentral

20.

Blumberg DM, Prager AJ, Liebmann JM, Cioffi GA, De Moraes CG. Cost-related medication nonadherence and cost-saving behaviors among patients with glaucoma before and after the implementation of medicare part D. JAMA Ophthalmol. 2015;133(9):985–96. https://doi.org/10.1001/jamaophthalmol.2015.1671.CrossRefPubMed

21.

Stewart WC, Stewart JA, Nelson LA. Ocular surface disease in patients with ocular hypertension and glaucoma. Curr Eye Res. 2011;36(5):391–8. https://doi.org/10.3109/02713683.2011.562340.CrossRefPubMed

22.

Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma. 2008;17(5):350–5. https://doi.org/10.1097/IJG.0b013e31815c5f4f.CrossRefPubMed

23.

Honjo M, Inatani M, Kido N, et al. A myosin light chain kinase inhibitor, ML-9, lowers the intraocular pressure in rabbit eyes. Exp Eye Res. 2002;75(2):135–42. https://doi.org/10.1006/exer.2002.2009.CrossRefPubMed

24.

Vittitow JL, Garg R, Rowlette L-LS, Epstein DL, O’Brien ET, Borrás T. Gene transfer of dominant-negative RhoA increases outflow facility in perfused human anterior segment cultures. Mol Vis. 2002;8:32–44.PubMed

25.

Gong H, Yang C-YC. Morphological and hydrodynamic correlations with increasing outflow facility by rho-kinase inhibitor Y-27632. J Ocul Pharmacol Ther Off J Assoc Ocul Pharmacol Ther. 2014;30(2–3):143–53. https://doi.org/10.1089/jop.2013.0192.CrossRef

26.

Li G, Mukherjee D, Navarro I, et al. Visualization of conventional outflow tissue responses to netarsudil in living mouse eyes. Eur J Pharmacol. 2016. https://doi.org/10.1016/j.ejphar.2016.04.002.CrossRefPubMedPubMedCentral

27.

Rao PV, Deng P, Sasaki Y, Epstein DL. Regulation of myosin light chain phosphorylation in the trabecular meshwork: role in aqueous humour outflow facility. Exp Eye Res. 2005;80(2):197–206. https://doi.org/10.1016/j.exer.2004.08.029.CrossRefPubMed

28.

Abu-Hassan DW, Acott TS, Kelley MJ. The Trabecular Meshwork: A Basic Review of Form and Function. J Ocul Biol. 2014;2(1). https://doi.org/10.13188/2334-2838.1000017

29.

Tokushige H, Inatani M, Nemoto S, et al. Effects of topical administration of y-39983, a selective rho-associated protein kinase inhibitor, on ocular tissues in rabbits and monkeys. Invest Ophthalmol Vis Sci. 2007;48(7):3216–22. https://doi.org/10.1167/iovs.05-1617.CrossRefPubMed

30.

Ren R, Li G, Le TD, Kopczynski C, Stamer WD, Gong H. Netarsudil increases outflow facility in human eyes through multiple mechanisms. Invest Ophthalmol Vis Sci. 2016;57(14):6197–209. https://doi.org/10.1167/iovs.16-20189.CrossRefPubMedPubMedCentral

31.

Kazemi A, McLaren JW, Kopczynski CC, Heah TG, Novack GD, Sit AJ. The effects of netarsudil ophthalmic solution on aqueous humor dynamics in a randomized study in humans. J Ocul Pharmacol Ther Off J Assoc Ocul Pharmacol Ther. 2018;34(5):380–6. https://doi.org/10.1089/jop.2017.0138.CrossRef

32.

Wang R-F, Williamson JE, Kopczynski C, Serle JB. Effect of 0.04% AR-13324, a ROCK, and norepinephrine transporter inhibitor, on aqueous humor dynamics in normotensive monkey eyes. J Glaucoma. 2015;24(1):51–4. https://doi.org/10.1097/IJG.0b013e3182952213.CrossRefPubMed

33.

Honjo M, Tanihara H, Kameda T, Kawaji T, Yoshimura N, Araie M. Potential role of Rho-associated protein kinase inhibitor Y-27632 in glaucoma filtration surgery. Invest Ophthalmol Vis Sci. 2007;48(12):5549–57. https://doi.org/10.1167/iovs.07-0878.CrossRefPubMed

34.

Tokushige H, Waki M, Takayama Y, Tanihara H. Effects of Y-39983, a selective Rho-associated protein kinase inhibitor, on blood flow in optic nerve head in rabbits and axonal regeneration of retinal ganglion cells in rats. Curr Eye Res. 2011;36(10):964–70. https://doi.org/10.3109/02713683.2011.599106.CrossRefPubMed

35.

Okumura N, Okazaki Y, Inoue R, et al. Effect of the rho-associated kinase inhibitor eye drop (Ripasudil) on corneal endothelial wound healing. Invest Ophthalmol Vis Sci. 2016;57(3):1284–92. https://doi.org/10.1167/iovs.15-18586.CrossRefPubMed

36.

Arita R, Hata Y, Ishibashi T. ROCK as a therapeutic target of diabetic retinopathy. J Ophthalmol. 2010;2010: 175163. https://doi.org/10.1155/2010/175163.CrossRefPubMedPubMedCentral

37.

FDA Approves Rhopressa. https://www.drugs.com/newdrugs/aerie-pharmaceuticals-announces-u-s-fda-approval-rhopressa-netarsudil-ophthalmic-solution-0-02-4663.html. Published 2017. Accessed 17 Dec 2023

38.

Serle JB, Katz LJ, McLaurin E, et al. Two phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure: rho kinase elevated IOP treatment trial 1 and 2 (ROCKET-1 and ROCKET-2). Am J Ophthalmol. 2018;186:116–27. https://doi.org/10.1016/j.ajo.2017.11.019.CrossRefPubMed

39.

Khouri AS, Serle JB, Bacharach J, et al. Once-daily netarsudil versus twice-daily timolol in patients with elevated intraocular pressure: the randomized phase 3 ROCKET-4 study. Am J Ophthalmol. 2019;204:97–104. https://doi.org/10.1016/j.ajo.2019.03.002.CrossRefPubMed

40.

Bacharach J, Dubiner HB, Levy B, Kopczynski CC, Novack GD. Double-masked, randomized, dose-response study of AR-13324 versus latanoprost in patients with elevated intraocular pressure. Ophthalmology. 2015;122(2):302–7. https://doi.org/10.1016/j.ophtha.2014.08.022.CrossRefPubMed

41.

Pham AT, Bradley C, Casey C, Jampel HD, Ramulu PY, Yohannan J. Effectiveness of netarsudil versus brimonidine in eyes already being treated with glaucoma medications at a single academic tertiary care practice: a comparative study. Curr Ther Res Clin Exp. 2023;98: 100689. https://doi.org/10.1016/j.curtheres.2022.100689.CrossRefPubMed

42.

Aerie Pharmaceuticals Receives FDA Approval of Rocklatan for Reduction of IOP. https://eyewire.news/articles/aerie-pharmaceuticals-receives-fda-approval-of-rocklatan-for-reduction-of-iop/?c4src=article:infinite-scroll. Published 2019. Accessed 17 Dec 2023

43.

Lewis RA, Levy B, Ramirez N, Kopczynski CC, Usner DW, Novack GD. Fixed-dose combination of AR-13324 and latanoprost: a double-masked, 28-day, randomised, controlled study in patients with open-angle glaucoma or ocular hypertension. Br J Ophthalmol. 2016;100(3):339–44. https://doi.org/10.1136/bjophthalmol-2015-306778. Accessed 17 Dec 2023CrossRefPubMed

44.

Brubaker JW, Teymoorian S, Lewis RA, et al. One year of netarsudil and latanoprost fixed-dose combination for elevated intraocular pressure: phase 3, randomized MERCURY-1 study. Ophthalmol Glaucoma. 2020;3(5):327–38. https://doi.org/10.1016/j.ogla.2020.05.008.CrossRefPubMed

45.

Walters TR, Ahmed IIK, Lewis RA, et al. Once-Daily netarsudil/latanoprost fixed-dose combination for elevated intraocular pressure in the randomized phase 3 MERCURY-2 study. Ophthalmol Glaucoma. 2019;2(5):280–9. https://doi.org/10.1016/j.ogla.2019.03.007.CrossRefPubMed

46.

Asrani S, Bacharach J, Holland E, et al. Fixed-dose combination of netarsudil and latanoprost in ocular hypertension and open-angle glaucoma: pooled efficacy/safety analysis of phase 3 MERCURY-1 and -2. Adv Ther. 2020;37(4):1620–31. https://doi.org/10.1007/s12325-020-01277-2.CrossRefPubMedPubMedCentral

47.

LLC MS. Market Scope 2022 Glaucoma Pharmaceuticals Report. Missouri; 2022.

48.

Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Araie M. Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol. 2013;156(4):731–6. https://doi.org/10.1016/j.ajo.2013.05.016.CrossRefPubMed

49.

Tanihara H, Inoue T, Yamamoto T, et al. One-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-angle glaucoma and ocular hypertension. Acta Ophthalmol. 2016;94(1):e26-34. https://doi.org/10.1111/aos.12829.CrossRefPubMed

50.

Jethva J, Bhagat P, Prajapati K, Tank G. Safety, efficacy, and patient selection of ripasudil in patients with uncontrolled glaucoma with maximum conventional medical therapy. Indian J Ophthalmol. 2022;70(6):2020–3. https://doi.org/10.4103/ijo.IJO_3145_21.CrossRefPubMedPubMedCentral

51.

Naik M, Kapur M, Gupta V, Sethi H, Srivastava K. Ripasudil endgame: role of rho-kinase inhibitor as a last-ditch-stand towards maximally tolerated medical therapy to a patient of advanced glaucoma. Clin Ophthalmol. 2021;15:2683–92. https://doi.org/10.2147/OPTH.S318897.CrossRefPubMedPubMedCentral

52.

Futakuchi A, Inoue T, Fujimoto T, Inoue-Mochita M, Kawai M, Tanihara H. The effects of ripasudil (K-115), a Rho kinase inhibitor, on activation of human conjunctival fibroblasts. Exp Eye Res. 2016;149:107–15. https://doi.org/10.1016/j.exer.2016.07.001.CrossRefPubMed

53.

Garnock-Jones KP. Ripasudil: first global approval. Drugs. 2014;74(18):2211–5. https://doi.org/10.1007/s40265-014-0333-2.CrossRefPubMed

54.

Okumura N, Okazaki Y, Inoue R, et al. Rho-associated kinase inhibitor eye drop (Ripasudil) transiently alters the morphology of corneal endothelial cells. Invest Ophthalmol Vis Sci. 2015;56(12):7560–7. https://doi.org/10.1167/iovs.15-17887.CrossRefPubMed

55.

Chihara E, Dimitrova G, Chihara T. Increase in the OCT angiographic peripapillary vessel density by ROCK inhibitor ripasudil instillation: a comparison with brimonidine. Graefe’s Arch Clin Exp Ophthalmol Albr von Graefes Arch fur Klin und Exp Ophthalmol. 2018;256(7):1257–64. https://doi.org/10.1007/s00417-018-3945-5.CrossRef

56.

Yamamoto K, Maruyama K, Himori N, et al. The novel Rho kinase (ROCK) inhibitor K-115: a new candidate drug for neuroprotective treatment in glaucoma. Invest Ophthalmol Vis Sci. 2014;55(11):7126–36. https://doi.org/10.1167/iovs.13-13842.CrossRefPubMed

57.

Kaneko Y, Ohta M, Isobe T, Nakamura Y, Mizuno K. Additive intraocular pressure-lowering effects of ripasudil with glaucoma therapeutic agents in rabbits and monkeys. J Ophthalmol. 2017;2017:7079645. https://doi.org/10.1155/2017/7079645.CrossRefPubMedPubMedCentral

58.

Tanihara H, Yamamoto T, Aihara M, et al. Ripasudil-brimonidine Fixed-dose combination vs. ripasudil or brimonidine; two phase 3 randomized clinical trials. Am J Ophthalmol. 2022. https://doi.org/10.1016/j.ajo.2022.11.017.CrossRefPubMed

59.

Tanihara H, Inoue T, Yamamoto T, et al. Additive Intraocular pressure-lowering effects of the rho kinase inhibitor ripasudil (K-115) combined with timolol or latanoprost: a report of 2 randomized clinical trials. JAMA Ophthalmol. 2015;133(7):755–61. https://doi.org/10.1001/jamaophthalmol.2015.0525.CrossRefPubMed

60.

Ha A, Kim YK, Jeoung JW, et al. Sovesudil (locally acting rho kinase inhibitor) for the treatment of normal-tension glaucoma: the randomized phase II study. Acta Ophthalmol. 2022;100(2):e470–7. https://doi.org/10.1111/aos.14949.CrossRefPubMed

61.

Tanihara H, Inatani M, Honjo M, Tokushige H, Azuma J, Araie M. Intraocular pressure-lowering effects and safety of topical administration of a selective ROCK inhibitor, SNJ-1656, in healthy volunteers. Arch Ophthalmol (Chicago, Ill 1960). 2008;126(3):309–15. https://doi.org/10.1001/archophthalmol.2007.76.CrossRef

62.

Inoue T, Tanihara H, Tokushige H, Araie M. Efficacy and safety of SNJ-1656 in primary open-angle glaucoma or ocular hypertension. Acta Ophthalmol. 2015;93(5):e393–5. https://doi.org/10.1111/aos.12641.CrossRefPubMed

63.

Takahashi Y, Inoue T, Imai S, Otsuka T, Arakawa R, Naito A. WP-1303 (H-1129), a novel antiglaucoma agent, lowers intraocular pressure by increasing conventional outflow in rabbits and monkeys. Invest Ophthalmol Vis Sci. 2018;59(9):4714.

64.

CRO C. Announcement of the Discontinuation of Development in Japan with WP-1303 (H-1129). https://www.cmocro.com/news_detail/Announcement+of+the+Discontinuation+of+Development+in+Japan+/418503/index.html. Published 2019. Accessed 17 Dec 2023

65.

Ren R, Humphrey AA, Kopczynski C, Gong H. Rho kinase inhibitor AR-12286 reverses steroid-induced changes in intraocular pressure, effective filtration areas, and morphology in mouse eyes. Invest Ophthalmol Vis Sci. 2023;64(2):7. https://doi.org/10.1167/iovs.64.2.7.CrossRefPubMedPubMedCentral

66.

Rao VP, Epstein DL. Rho GTPase/Rho kinase inhibition as a novel target for the treatment of glaucoma. BioDrugs. 2007;21(3):167–77. https://doi.org/10.2165/00063030-200721030-00004.CrossRefPubMed

67.

Levy B, Ramirez N, Novack GD, Kopczynski C. Ocular hypotensive safety and systemic absorption of AR-13324 ophthalmic solution in normal volunteers. Am J Ophthalmol. 2015;159(5):980-5.e1. https://doi.org/10.1016/j.ajo.2015.01.026.CrossRefPubMed

68.

Asrani S, Robin AL, Serle JB, et al. Netarsudil/latanoprost fixed-dose combination for elevated intraocular pressure: three-month data from a randomized phase 3 trial. Am J Ophthalmol. 2019;207:248–57. https://doi.org/10.1016/j.ajo.2019.06.016.CrossRefPubMed

69.

Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Araie M. Phase 1 clinical trials of a selective Rho kinase inhibitor, K-115. JAMA Ophthalmol. 2013;131(10):1288–95. https://doi.org/10.1001/jamaophthalmol.2013.323.CrossRefPubMed

70.

Lewis RA, Levy B, Ramirez N, Kopczynski CC, Usner DW, Novack GD. Fixed-dose combination of AR-13324 and latanoprost: a double-masked, 28-day, randomised, controlled study in patients with open-angle glaucoma or ocular hypertension. Br J Ophthalmol. 2015. https://doi.org/10.1136/bjophthalmol-2015-306778.CrossRefPubMed

71.

Arnold JJ, Hansen MS, Gorman GS, et al. The effect of rho-associated kinase inhibition on the ocular penetration of timolol maleate. Invest Ophthalmol Vis Sci. 2013;54(2):1118–26. https://doi.org/10.1167/iovs.12-10583.CrossRefPubMedPubMedCentral

Title: Rho Kinase Inhibitors: Strategies in Glaucoma Treatment in Older Adults
Authors: Emily Schehlein
Alan Robin
Publication date: 28-02-2024
Publisher: Springer International Publishing
Keywords: Glaucoma
Latanoprost
Timolol
Brimonidine
Published in: Drugs & Aging / Issue 5/2024
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI: https://doi.org/10.1007/s40266-024-01107-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2024

Measuring Quality of Life in Deprescribing Trials: A Scoping Review

Toxicity in Older Patients with Cancer Receiving Immunotherapy: An Observational Study

Rosacea in Older Adults and Pharmacologic Treatments

Lipid-Lowering Medications are Associated with Reduced Sarcopenia-Related Quality of Life in Older Adults with Hyperlipidemia

Association of Tumor Necrosis Factor-α Inhibitors with Incident Dementia: Analysis Based on Population-Based Cohort Studies

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage